Quintiles' ability to provide customers with actionable early-stage data to make better development decisions faster has taken a significant step forward with the closing of the previously announced agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory.
“Adding Advion's world-class bioanalytical testing capabilities and expertise to our existing CAP-accredited central labs network creates a global one-stop solution for lab testing across the development spectrum”
Now known as Advion Bioanalytical Labs, a Quintiles company, the group provides Good Laboratory Practice (GLP) pharmacokinetic/pharmacodynamic (PK/PD) testing and other services to biopharma companies worldwide.
"Adding Advion's world-class bioanalytical testing capabilities and expertise to our existing CAP-accredited central labs network creates a global one-stop solution for lab testing across the development spectrum," said Thomas Wollman, Senior Vice President, Quintiles Global Laboratories. "I believe we now have unsurpassed abilities to help companies gather early-stage data and gain insights aimed at reducing the risk of failure in expensive later-stage trials."
Tom Kurz, Advion BioServices President and co-founder, said: "Quintiles' strong commitment to science, and to grow and expand our bioanalytical services globally, were two key drivers behind this agreement. We look forward to helping even more biopharma customers improve the efficiency and productivity of drug development now that we're part of Quintiles."
Advion BioServices has more than 180 employees at facilities in Ithaca, N.Y.; Manassas, Va.; and Indianapolis.
Quintiles Global Laboratories supports global and regional trials in almost every country in the world with wholly owned facilities in the U.S., Europe, South Africa, India, China, Singapore and Japan, and a tightly coordinated network of affiliate laboratories in Argentina and Brazil.